Priority areas for cannabis and cannabinoid product research in South Africa.
作者信息
Augustine Tanya N, Cairns Carel J, Chetty Sean, Dannatt Lisa G, Gravett Nadine, Grey Glenda, Grobler Gerhard, Jafta Zukiswa, Kamerman Peter, Lopes John, Matsabisa Motlalepula G, Mugabo Pierre, Mulder Michelle, Parry Charles, Rataemane Solomon, Siegfried Nandi, Steenkamp Vanessa, Thomas Eileen, Van Zyl-Smit Richard
机构信息
School of Anatomical Sciences, Faculty of Health Sciences, University of the Witwatersrand.
出版信息
Afr J Prim Health Care Fam Med. 2018 Jun 21;10(1):e1-e3. doi: 10.4102/phcfm.v10i1.1711.
Abstract
No abstract available.
摘要
相似文献
1
Priority areas for cannabis and cannabinoid product research in South Africa.
Afr J Prim Health Care Fam Med. 2018 Jun 21;10(1):e1-e3. doi: 10.4102/phcfm.v10i1.1711.
2
Medicinal cannabis and painful sensory neuropathy.
Virtual Mentor. 2013 May 1;15(5):466-9. doi: 10.1001/virtualmentor.2013.15.5.oped1-1305.
3
Cannabis and cannabinoids.
Med Lett Drugs Ther. 2016 Aug 1;58(1500):97-8.
4
Cannabinoids: Medical implications.
Ann Med. 2016;48(3):128-41. doi: 10.3109/07853890.2016.1145794. Epub 2016 Feb 25.
5
Sequelae of Cannabis as Medicine.
Pain Med. 2015 Jul;16(7):1447-9. doi: 10.1111/pme.12736. Epub 2015 Jun 24.
6
The medicinal use of cannabis and cannabinoids--an international cross-sectional survey on administration forms.
J Psychoactive Drugs. 2013 Jul-Aug;45(3):199-210. doi: 10.1080/02791072.2013.805976.
7
Plant, synthetic, and endogenous cannabinoids in medicine.
Annu Rev Med. 2006;57:553-74. doi: 10.1146/annurev.med.57.011205.135648.
8
Re-branding cannabis: the next generation of chronic pain medicine?
Pain Manag. 2015;5(1):13-21. doi: 10.2217/pmt.14.49.
9
Medical uses of marijuana (Cannabis sativa): fact or fallacy?
Br J Biomed Sci. 2015;72(2):85-91. doi: 10.1080/09674845.2015.11666802.
10
Medical Marijuana and Chronic Pain: a Review of Basic Science and Clinical Evidence.
Curr Pain Headache Rep. 2015 Oct;19(10):50. doi: 10.1007/s11916-015-0524-x.
引用本文的文献
1
Phytocannabinoids: Pharmacological effects, biomedical applications, and worldwide prospection.
J Tradit Complement Med. 2023 Aug 26;13(6):575-587. doi: 10.1016/j.jtcme.2023.08.006. eCollection 2023 Nov.
2
Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review.
IBRO Neurosci Rep. 2021 Jan 25;10:109-118. doi: 10.1016/j.ibneur.2021.01.004. eCollection 2021 Jun.
本文引用的文献
1
The Question of Clinical Equipoise and Patients' Best Interests.
AMA J Ethics. 2015 Dec 1;17(12):1108-15. doi: 10.1001/journalofethics.2015.17.12.ecas1-1512.
2
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.
JAMA. 2015;313(24):2456-73. doi: 10.1001/jama.2015.6358.
3
A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment.
Eur J Pain. 2014 Aug;18(7):999-1012. doi: 10.1002/j.1532-2149.2013.00445.x. Epub 2014 Jan 13.
4
A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.
J Neurol. 2013 Apr;260(4):984-97. doi: 10.1007/s00415-012-6739-4. Epub 2012 Nov 21.
5
Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations.
Pain. 2012 Jun;153(6):1148-1158. doi: 10.1016/j.pain.2012.03.003. Epub 2012 Apr 9.
6
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.
BMJ. 2008 Apr 26;336(7650):924-6. doi: 10.1136/bmj.39489.470347.AD.
Zotero 插件